Vir Biotechnology (NASDAQ:VIR) Trading Up 4.8% – Should You Buy?

Vir Biotechnology, Inc. (NASDAQ:VIR)’s share price rose 4.8% during trading on Tuesday . The stock traded as high as $11.27 and last traded at $11.4620. 293,535 shares traded hands during mid-day trading, a decline of 88% from the average session volume of 2,443,843 shares. The stock had previously closed at $10.94.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on VIR shares. Morgan Stanley set a $25.00 price objective on shares of Vir Biotechnology in a report on Thursday, August 6th. Leerink Partners upped their price target on shares of Vir Biotechnology from $20.00 to $21.00 and gave the company an “outperform” rating in a research report on Wednesday, June 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Vir Biotechnology in a report on Wednesday, July 8th. Wall Street Zen raised Vir Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, HC Wainwright reiterated a “buy” rating on shares of Vir Biotechnology in a research note on Monday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.57.

Vir Biotechnology Stock Performance

The firm has a 50 day simple moving average of $9.62 and a two-hundred day simple moving average of $9.34. The stock has a market cap of $1.93 billion, a P/E ratio of -6.16 and a beta of 1.66.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Wednesday, August 5th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.14. The business had revenue of $238.95 million during the quarter, compared to analysts’ expectations of $135.88 million. Vir Biotechnology had a negative return on equity of 29.99% and a negative net margin of 638.88%.The company’s quarterly revenue was up 19582.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.80) earnings per share. As a group, equities research analysts predict that Vir Biotechnology, Inc. will post -1.84 EPS for the current year.

Hedge Funds Weigh In On Vir Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Fiduciary Financial Advisors bought a new position in Vir Biotechnology in the second quarter valued at $29,000. Raymond James Financial Inc. acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth about $35,000. UMB Bank n.a. raised its holdings in shares of Vir Biotechnology by 1,418.7% in the 4th quarter. UMB Bank n.a. now owns 7,062 shares of the company’s stock valued at $43,000 after purchasing an additional 6,597 shares during the period. CWM LLC lifted its stake in Vir Biotechnology by 23.0% in the 4th quarter. CWM LLC now owns 8,804 shares of the company’s stock valued at $53,000 after purchasing an additional 1,646 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in Vir Biotechnology during the fourth quarter worth about $60,000. 65.32% of the stock is owned by institutional investors.

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.